Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High – Should You Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $38.13 and last traded at $37.80, with a volume of 36516 shares traded. The stock had previously closed at $36.49.

Analysts Set New Price Targets

A number of analysts have recently issued reports on KNSA shares. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday. They issued a “buy” rating and a $60.00 price target for the company. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 7th. Finally, Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $44.29.

Kiniksa Pharmaceuticals International Stock Up 4.0%

The stock has a market cap of $2.81 billion, a P/E ratio of 946.61 and a beta of 0.20. The firm’s 50-day moving average is $33.37 and its two-hundred day moving average is $28.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 138,614 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the transaction, the chief operating officer owned 49,915 shares in the company, valued at $1,657,178. This trade represents a 73.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael R. Megna sold 17,000 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the transaction, the chief accounting officer owned 33,041 shares in the company, valued at approximately $1,068,876.35. This trade represents a 33.97% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 561,371 shares of company stock valued at $18,825,009. 53.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $31,000. Tower Research Capital LLC TRC grew its stake in shares of Kiniksa Pharmaceuticals International by 1,539.1% in the second quarter. Tower Research Capital LLC TRC now owns 25,275 shares of the company’s stock worth $699,000 after acquiring an additional 23,733 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the last quarter. Lazard Asset Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 428.8% in the second quarter. Lazard Asset Management LLC now owns 15,181 shares of the company’s stock worth $420,000 after acquiring an additional 12,310 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $1,640,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.